NEI Research News

During Low Vision Awareness Month, the National Eye Institute (NEI), part of the National Institutes of Health, is highlighting new technologies and tools in the works to help the 4.1 million Americans living with low vision or blindness.

NEI research fellow Nathan Hotaling, PhD, has been awarded a $65,000 grant from the Knights Templar Eye Foundation to develop a stem cell-based system to study Best disease, a genetic disorder that can cause progressive vision loss.

Columbia University Medical Center (CUMC) and University of Iowa scientists have used a new gene-editing technology called CRISPR to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition.

A new technique that has the potential to treat inherited diseases by removing genetic defects has been shown for the first time to hinder retinitis pigmentosa, a degenerative eye disease with no known cure that can lead to blindness.

Retinal implants that deliver longer pulses of electrical current may noticeably improve image sharpness for individuals who have lost their sight due to retinitis pigmentosa, according to a new study.

Gene therapy preserved vision in a study involving dogs with naturally occurring, late-stage retinitis pigmentosa, according to research funded by the National Eye Institute (NEI), part of the National Institutes of Health.

When people lose the ability to see, how do the visual parts of the brain change in response? And if they regain their sight, are the changes reversed?

Spider-like cells inside the brain, spinal cord and eye hunt for invaders, capturing and then devouring them. These cells, called microglia, often play a beneficial role by helping to clear trash and protect the central nervous system against infection.

A delegation from the University of the Philippines (UP) and the Philippine National Institutes of Health recently visited NEI on May 21, 2015. It was an opportunity to renew old collaborations and discuss new ones...

The National Eye Institute (NEI) recently launched the first-ever human gene therapy trial for the vision disorder X-linked retinoschisis (XLRS). Researchers are conducting the trial at the National Institutes of Health Clinical Research Center in...